Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPASS Pathways plcCMPS · Entity 4567 | Director | May 27, 2026 | May 29, 2026 |
| Eucrates Biomedical Acquisition Corp.EUCR · Entity 145040 | Director | October 23, 2020 | October 23, 2020 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | September 15, 2026 | September 17, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Chief Financial Officer | February 03, 2021 | February 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPASS Pathways plc
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26 | Direct | 21,110 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 21,110 · Balance 21,110 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Eucrates Biomedical Acquisition Corp.
Report date October 23, 2020 · Filed October 23, 2020
This filing explicitly reported no securities owned.
Mineralys Therapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,200 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 3,000 · Balance 9,200 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. Row 2 · 2026-09-15 · Sale · Disposed 3,000 · Balance 6,200 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.02 · Expires 2033-09-13 | Direct | 35,000 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 3,000 · Balance 35,000 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. F2: The stock option vests in 36 monthly installments beginning on October 13, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.
F2: The stock option vests in 36 monthly installments beginning on October 13, 2023.
Syndax Pharmaceuticals Inc
Report date February 03, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.36 · Expires 2031-02-03 | Direct | 95,000 |
Reported balance
After 2021-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-03 · Grant · Acquired 95,000 · Balance 95,000 F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LogicBio Therapeutics, Inc.
Report date November 16, 2022 · Filed November 18, 2022
Section 16 reporting ended · disclosed 2022-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-06-17 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F1: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc.(the "Company'), subject to the Reporting Person's continued service with the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc.(the "Company'), subject to the Reporting Person's continued service with the Company on the vesting date.
F2: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 21:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,000 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001816952-26-000005 · wk-form4_1789681270.xml · derivative · entry 3 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 3,000 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 21:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 3,000 | $28.58 | $85,740.00 |
DisclosureSEC source: 0001816952-26-000005 · wk-form4_1789681270.xml · nonDerivative · entry 2 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,200 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 21:41 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,000 | $12.02 | $36,060.00 |
DisclosureSEC source: 0001816952-26-000005 · wk-form4_1789681270.xml · nonDerivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,000 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001933414-26-000093 · wk-form4_1781745479.xml · derivative · entry 3 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 3,000 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001933414-26-000093 · wk-form4_1781745479.xml · nonDerivative · entry 2 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,200 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 01:18 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,000 | $12.02 | $36,060.00 |
DisclosureSEC source: 0001933414-26-000093 · wk-form4_1781745479.xml · nonDerivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:31 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 21,110 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001816952-26-000004 · wk-form4_1780090300.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,110 Underlying: Ordinary Shares · 21,110 shares Expires 2036-05-26 F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:53 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 3,000 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001816952-26-000002 · wk-form4_1775170385.xml · derivative · entry 3 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 3,000 shares Expires 2033-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:53 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001816952-26-000002 · wk-form4_1775170385.xml · nonDerivative · entry 2 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,200 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 22:53 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 3,000 | $12.02 | $36,060.00 |
DisclosureSEC source: 0001816952-26-000002 · wk-form4_1775170385.xml · nonDerivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 8,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001933414-26-000042 · wk-form4_1771634842.xml · derivative · entry 2 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F2 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 21, 2026 00:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000042 · wk-form4_1771634842.xml · nonDerivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 00:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000150 · wk-form4_1763078481.xml · derivative · entry 4 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,900 Underlying: Common Stock · 15,000 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in 12 monthly installments following the date of grant. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 00:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 4,885 | $46.36 | $226,446.13 |
DisclosureSEC source: 0001933414-25-000150 · wk-form4_1763078481.xml · nonDerivative · entry 3 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.19 to $46.70. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 00:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,115 | $45.81 | $463,350.95 |
DisclosureSEC source: 0001933414-25-000150 · wk-form4_1763078481.xml · nonDerivative · entry 2 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,885 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.19 to $46.18. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 00:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 15,000 | $10.20 | $153,000.00 |
DisclosureSEC source: 0001933414-25-000150 · wk-form4_1763078481.xml · nonDerivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 12:18 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001816590-25-000071 · wk-form4_1749817118.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 23:58 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000013 · wk-form4_1740441514.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,900 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| May 22, 2024 Filed May 23, 2024 20:21 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 22,000 | $0.00 Strike: $12.52 | $0.00 |
DisclosureSEC source: 0001933414-24-000020 · wk-form4_1716495678.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting. Read SEC document |
| May 09, 2024 Filed May 13, 2024 10:44 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $8.54 | $0.00 |
DisclosureSEC source: 0001816590-24-000095 · wk-form4_1715597030.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 22:58 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0001816952-23-000005 · wk-form4_1695250693.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Ordinary Shares · 52,000 shares Expires 2033-09-17 F1 · derivative.exercise_date: The share option vests in equal monthly installments over three years, with the first vesting on October 18, 2023. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 20:13 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 44,000 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001933414-23-000079 · wf-form4_169472241630395.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-09-13 F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on October 13, 2023. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 02:07 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Disposition to issuerStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0000899243-22-036295 · doc4.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F1 · derivative.exercise_date: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc.(the "Company'), subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document |
| June 17, 2022 Filed Jul 5, 2022 10:59 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-040376 · doc4.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F1 · shares: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 00:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-21-040427 · doc4.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-11 F1 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:22 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001562180-21-000933 · primarydocument.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:46 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0000899243-20-033748 · doc4.xml · derivative · entry 1 Karydas Daphne · CIK 0001816952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, December 10, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.